What is the global carriage rate of Carbapenem-Resistant Enterobacteriaceae (CRE) in feces?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The global carriage rate of Carbapenem-Resistant Enterobacteriaceae (CRE) in feces is approximately 9.6%, with higher rates observed in hospitalized patients, particularly those in intensive care units or with prolonged hospital stays, as reported in a recent study from China 1.

Key Findings

  • The overall fecal carriage rate of CRE was 9.6% in a study of 685 stool samples from four provinces in China, with 4.26% in healthy individuals and 10.84% in hospitalized patients 1.
  • The highest prevalence of CRE was found in Henan province, with a rate of 18.35% 1.
  • A study from Southern Iran reported a high frequency of CRE fecal carriage among ICU hospitalized patients, with an overall carriage rate of 28.2% and a CRE acquisition rate of 6.1% 2.

Risk Factors

  • Previous antibiotic exposure, especially carbapenems, fluoroquinolones, and third-generation cephalosporins, is a significant risk factor for CRE carriage 1, 2.
  • Hospitalization, invasive procedures, immunosuppression, and travel to high-prevalence regions are also risk factors for CRE carriage 1, 2.

Importance of Detection

  • The detection of CRE in feces is significant as carriers can serve as reservoirs for transmission in healthcare settings, even when asymptomatic 1, 2.
  • Infection control measures and antimicrobial stewardship are crucial to limit the spread of CRE 1, 2.

Regional Variations

  • The prevalence of CRE varies significantly by region, with higher rates observed in South Asia, the Mediterranean, and parts of Latin America compared to North America and Northern Europe 1, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.